National Health Investors Inc NHI
We take great care to ensure that the data presented and summarized in this overview for NATIONAL HEALTH INVESTORS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NHI
View all-
Vanguard Group Inc Valley Forge, PA6.14MShares$475 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.41MShares$342 Million0.01% of portfolio
-
State Street Corp Boston, MA1.87MShares$145 Million0.01% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.77MShares$137 Million0.07% of portfolio
-
Macquarie Group LTD Australia, C31.09MShares$84.6 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA1.09MShares$84.1 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC850KShares$65.8 Million0.01% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA729KShares$56.5 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX608KShares$47.1 Million0.01% of portfolio
-
Lasalle Investment Management Securities LLC Baltimore, MD601KShares$46.6 Million1.76% of portfolio
Latest Institutional Activity in NHI
Top Purchases
Top Sells
About NHI
Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals.
Insider Transactions at NHI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 27
2024
|
W Andrew Adams Director |
SELL
Other acquisition or disposition
|
Indirect |
12,635
-100.0%
|
-
|
Sep 25
2024
|
Kristin Sallee Gaines SVP/Chief Transaction Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
48,665
-45.65%
|
$4,087,860
$84.66 P/Share
|
Sep 25
2024
|
Kristin Sallee Gaines SVP/Chief Transaction Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+17.55%
|
$3,795,000
$69.2 P/Share
|
Sep 18
2024
|
David L Travis SVP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,406
-39.33%
|
$884,510
$85.15 P/Share
|
Sep 18
2024
|
David L Travis SVP/Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+16.05%
|
$828,000
$69.2 P/Share
|
Sep 05
2024
|
D. Eric Mendelsohn CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
130,461
-59.5%
|
$10,697,802
$82.1 P/Share
|
Sep 05
2024
|
D. Eric Mendelsohn CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
164,999
+16.91%
|
$8,909,946
$54.57 P/Share
|
Sep 03
2024
|
Robert T Webb Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
52,353
-46.74%
|
$4,188,240
$80.04 P/Share
|
Sep 03
2024
|
Robert T Webb Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
70,000
+16.42%
|
$4,060,000
$58.77 P/Share
|
Sep 03
2024
|
John L Spaid CFO/EVP Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
49,637
-56.35%
|
$4,020,597
$81.43 P/Share
|
Sep 03
2024
|
John L Spaid CFO/EVP Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
62,167
+13.51%
|
$3,357,018
$54.57 P/Share
|
Aug 23
2024
|
Kevin Carlton Pascoe Chief Investment Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
101,230
-64.45%
|
$7,895,940
$78.63 P/Share
|
Aug 23
2024
|
Kevin Carlton Pascoe Chief Investment Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,167
+12.82%
|
$7,030,020
$60.2 P/Share
|
Aug 23
2024
|
John L Spaid CFO/EVP Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
65,463
-71.64%
|
$5,106,114
$78.63 P/Share
|
Aug 23
2024
|
John L Spaid CFO/EVP Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
73,333
+23.84%
|
$4,766,645
$65.25 P/Share
|
Aug 23
2024
|
James R Jobe Director |
SELL
Payment of exercise price or tax liability
|
Direct |
31,289
-52.17%
|
$2,440,542
$78.63 P/Share
|
Aug 23
2024
|
James R Jobe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+23.15%
|
$2,475,000
$55.3 P/Share
|
Aug 23
2024
|
David L Travis SVP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,839
-61.23%
|
$1,781,442
$78.63 P/Share
|
Aug 23
2024
|
David L Travis SVP/Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,300
+18.19%
|
$1,605,900
$53.58 P/Share
|
Aug 16
2024
|
Tracy M J Colden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+30.13%
|
$2,565,000
$57.31 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 15K shares |
---|---|
Exercise of conversion of derivative security | 720K shares |
Open market or private purchase | 10.4K shares |
Payment of exercise price or tax liability | 580K shares |
---|---|
Other acquisition or disposition | 12.6K shares |